Post‑COVID‑19 neuropsychiatric sequelae—including cognitive deficits, anxiety and depression—are recognised components of the multisystem long COVID syndrome and are associated with worse functional outcomes and productivity losses. The precise pathogenesis of these post‑acute manifestations is not established, and diagnostic or prognostic biomarkers remain lacking. This study protocol aims to identify brain regions with altered function in people with post‑acute COVID‑19 neurological and neuropsychiatric symptoms and to evaluate associations between functional brain changes, acute serum inflammatory mediators, and brain injury biomarkers.
This work is a secondary analysis of data from the COVID‑19 Clinical Neuroscience Study (CNS), a large UK multicentre prospective observational study conducted during the pandemic. The CNS compared participants who were COVID‑19 positive with negative controls. The sub‑study uses the existing CNS dataset, which includes neuroimaging, blood biomarker data collected during the acute illness, and neuropsychiatric assessments performed post‑acutely and at follow‑up.
Participants received standardized neuropsychiatric testing post‑acutely and at follow‑up. Cognitive function is assessed with the Cognitron test battery. Depressive symptoms are measured using the PHQ‑9 and anxiety symptoms using the GAD‑7. These instruments provide quantitative symptom scores to be related to imaging and biomarker measures.
The protocol will use acute‑phase blood measurements of inflammatory mediators and brain injury biomarkers obtained during participants’ acute COVID‑19 illness. The study will explore correlations between these acute serum markers and later functional brain changes measured by resting‑state fMRI. Specific biomarker names and assay details were not reported in this protocol.
Resting‑state functional MRI data from CNS participants will be preprocessed and analysed using the DPABI (Data Processing & Analysis for Brain Imaging) toolbox. The preprocessing workflow and any site‑specific harmonization steps are to follow the DPABI pipeline. The primary neuroimaging metric for this analysis is Regional Homogeneity (ReHo), which quantifies local synchronization of spontaneous BOLD signal fluctuations.
The study will compute ReHo maps from preprocessed resting‑state fMRI data and examine associations between ReHo values and neuropsychiatric symptom measures (Cognitron scores, PHQ‑9, GAD‑7). The relationship between ReHo and acute serum inflammatory mediators and brain injury biomarkers will also be assessed. Details on thresholds for statistical significance, correction for multiple comparisons, covariates, and region‑of‑interest versus whole‑brain approaches were not specified in the protocol.
Regression analyses will be used to model the risk and protective factors for developing persistent cognitive and psychiatric sequelae after COVID‑19. Predictor variables will include imaging measures (ReHo), acute biomarker levels, and clinical covariates drawn from the CNS dataset. The protocol indicates the intention to use regression modelling but does not report the exact model specifications or planned covariates.
The study declares ethics approvals and participant consent were obtained. The research was registered with the East of England Cambridge research ethics committee with reference numbers REC reference 17/EE/0025; 22/EE/0230. The authors state compliance with relevant reporting guidelines. As this document is a protocol/secondary analysis plan, data availability is described as not applicable in this preprint.
The investigators anticipate that linking functional MRI measures of Regional Homogeneity with clinical symptomatology and acute serum biomarkers will provide new insights into the functional basis of post‑acute COVID‑19 neuropsychiatric manifestations and may identify candidate diagnostic or prognostic biomarkers. The protocol does not present results; it also omits specific details on which inflammatory or brain injury biomarkers will be used, exact statistical thresholds, and full preprocessing parameterization. These omissions mean that some methodological specifics will need to be clarified when results are reported.